MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 128610 | Name: Ainuovirine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ainuovirine is an antiviral agent.

Chemical Structure

Ainuovirine
Ainuovirine
CAS#1097628-00-6

Theoretical Analysis

MedKoo Cat#: 128610

Name: Ainuovirine

CAS#: 1097628-00-6

Chemical Formula: C18H19N3O3

Exact Mass: 325.1426

Molecular Weight: 325.37

Elemental Analysis: C, 66.45; H, 5.89; N, 12.91; O, 14.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Ainuovirine; KM-023; KM023; KM 023
IUPAC/Chemical Name
3-(3-ethyl-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-5-methylbenzonitrile
InChi Key
AYPIJAMXGVYYRQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H19N3O3/c1-5-21-15(14(10(2)3)17(23)20-18(21)24)16(22)13-7-11(4)6-12(8-13)9-19/h6-8,10H,5H2,1-4H3,(H,20,23,24)
SMILES Code
N#CC1=CC(C)=CC(C(C2=C(C(NC(N2CC)=O)=O)C(C)C)=O)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 325.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Peng Y, Zong Y, Wang D, Chen J, Chen ZS, Peng F, Liu Z. Current drugs for HIV-1: from challenges to potential in HIV/AIDS. Front Pharmacol. 2023 Oct 26;14:1294966. doi: 10.3389/fphar.2023.1294966. PMID: 37954841; PMCID: PMC10637376. 2: Xie X, Gan L, Fu Y, Song Y, Song C, Ren T, Ke C, Long H. Pharmacokinetics and Safety of Ainuovirine/Lamivudine/Tenofovir Combination Tablets in Young and Elderly Patients with Human Immunodeficiency Virus-1 Infection. Infect Dis Ther. 2023 Oct;12(10):2457-2469. doi: 10.1007/s40121-023-00877-z. Epub 2023 Oct 3. PMID: 37787861; PMCID: PMC10600068. 3: Su B, Gao G, Wang M, Lu Y, Li L, Chen C, Chen Y, Song C, Yu F, Li Y, Liu Y, Luo Y, He H, Cheng C, Xu L, Zhang T, Sun L, Liu A, Xia W, Qin Y, Zhao Q, Wei H, Cai W, Chen Y, Zhang F, Wu H. Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. Lancet Reg Health West Pac. 2023 Apr 24;36:100769. doi: 10.1016/j.lanwpc.2023.100769. PMID: 37547039; PMCID: PMC10398592. 4: Luo P, Jin J, Li J, Yin J, Jing X, Hou H, Ba H, Zhang Y. A comparative study based on ainuovirine/lamivudine/tenofovir against HIV-1. Int J STD AIDS. 2024 Dec;35(14):1103-1111. doi: 10.1177/09564624241282366. Epub 2024 Sep 13. PMID: 39269687. 5: Zhang F, Wu H, Cai W, Ma P, Zhao Q, Wei H, Lu H, Wang H, He S, Chen Z, Chen Y, Wang M, Wan W, Fu H, Qin H. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial. Lancet Reg Health West Pac. 2024 Jul 18;49:101143. doi: 10.1016/j.lanwpc.2024.101143. PMID: 39092318; PMCID: PMC11293588. 6: Han X, Sun J, Zhang Y, Jiang T, Zheng Q, Peng H, Wang Y, Xia W, Zhang T, Sun L, Yun X, Qin H, Wu H, Su B. Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals. Chin Med J (Engl). 2024 Oct 20;137(20):2473-2482. doi: 10.1097/CM9.0000000000002917. Epub 2024 Jun 27. PMID: 38934053; PMCID: PMC11479413. 7: Zhang Q, Chen Z, Wang Y, Peng Y, Tan S, Li Y, Cao G, Bignotti A, Wu S, Wang M. Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study. Front Med (Lausanne). 2024 Jan 8;10:1277059. doi: 10.3389/fmed.2023.1277059. PMID: 38259850; PMCID: PMC10800701. 8: Long H, He Q, Bi Y, Ke Y, Xie X, Zhao X, Tan S, Luo Y, Chen Z, Yu X, Li L. Efficacy and effect on lipid profiles of Ainuovirine-based regimen versus Efavirenz-based regimen in treatment-naïve people with HIV-1 at week 24: A real- world, retrospective, multi-center cohort study. Biosci Trends. 2024 Jun 6;18(2):176-186. doi: 10.5582/bst.2024.01070. Epub 2024 Apr 27. PMID: 38684402. 9: Guo L, Fu Y, Xie X, Yan W, Long H. Comparative Studies on the Efficacy and Safety of Ainuovirine-Based Versus Efavirenz-Based Antiretroviral Therapy in the Management of Persons Living with HIV: A Real-World Study in Guizhou, China. AIDS Res Hum Retroviruses. 2024 Aug;40(8):482-488. doi: 10.1089/AID.2024.0030. Epub 2024 Jun 3. PMID: 38753724. 10: Wang C, Yu X, Ke Y, Fu Y, Luo Y, Li Y, Bi Y, Chen X, Li L, Zhao X, Chen Z. Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0166823. doi: 10.1128/aac.01668-23. Epub 2024 Mar 14. PMID: 38483175; PMCID: PMC10989015.